Condition: Specific Advanced Solid Tumors · Sponsor: Acrivon Therapeutics
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
This description comes directly from the study's public registry record.
Mansoor R Mirza, MD · 617-207-8979 · ACR-2316ClinicalTrial@acrivon.com
Jeanie Tang · ACR-2316ClinicalTrial@acrivon.com
Always discuss trial participation with your own doctor first.
| HonorHealth Research Institute | Phoenix, Arizona, United States | Recruiting |
| Precision NextGen Oncology & Research Center | Beverly Hills, California, United States | Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Recruiting |
| Denver Health One | Denver, Colorado, United States | Recruiting |
| Florida Cancer Specialist | Sarasota, Florida, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Roswell Park Comprehensive Cancer Center | Buffalo, New York, United States | Recruiting |
| Montefiore Medical Centre | The Bronx, New York, United States | Recruiting |
| Carolina BioOncology Institute | Huntersville, North Carolina, United States | Recruiting |
| Rhode Island Hospital | Providence, Rhode Island, United States | Recruiting |
| Tennessee Oncology | Franklin, Tennessee, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06667141